Literature DB >> 31449513

Next-generation sequencing for the general cancer patient.

Monica Avila1, Funda Meric-Bernstam1.   

Abstract

Next-generation sequencing is a novel method of DNA sequencing that has become a cornerstone of precision oncology. This sequencing method detects differences in specific DNA sequences between a sample and a reference genome or matched normal DNA. In addition to single-nucleotide variants, other insertions, deletions, copy number changes, and fusions may be drivers of cancer growth, and thus represent therapeutic opportunities. As a result, genomic characterization has been increasingly used to guide treatment decisions, especially in patients with advanced disease. This review discusses the basic technologies involved in next-generation sequencing, the applications of this method, and limitations in the clinical realm.

Entities:  

Year:  2019        PMID: 31449513      PMCID: PMC6739831     

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  5 in total

1.  Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors.

Authors:  Dadasaheb Akolkar; Darshana Patil; Navin Srivastava; Revati Patil; Vineet Datta; Sachin Apurwa; Nitin Yashwante; Raja Dhasarathan; Rahul Gosavi; Jinumary John; Shabishta Khan; Ninad Jadhav; Priti Mene; Dhanashri Ahire; Sushant Pawar; Harshal Bodke; Subhraline Sahoo; Arun Nile; Dinesh Saindane; Harshal Darokar; Pradip Devhare; Ajay Srinivasan; Rajan Datar
Journal:  PLoS One       Date:  2021-02-08       Impact factor: 3.240

2.  The Importance of Targeted Next-Generation Sequencing Usage in Cytogenetically Normal Myeloid Malignancies.

Authors:  Emine Ikbal Atli; Hakan Gurkan; Engin Atli; Hakki Onur Kirkizlar; Sinem Yalcintepe; Selma Demir; Ufuk Demirci; Damla Eker; Cisem Mail; Rasime Kalkan; Ahmet Muzaffer Demir
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-01-01       Impact factor: 2.576

3.  Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model.

Authors:  Golnaz Ensieh Kazemi-Sefat; Mohammad Keramatipour; Mohammad Vaezi; Seyed Mohsen Razavi; Kaveh Kavousi; Amin Talebi; Shahrbanoo Rostami; Marjan Yaghmaei; Bahram Chahardouli; Saeed Talebi; Kazem Mousavizadeh
Journal:  Sci Rep       Date:  2022-07-27       Impact factor: 4.996

4.  Immune checkpoint inhibitor therapy in a liver transplant recipient with autoimmune disease and metastatic cutaneous squamous cell carcinoma.

Authors:  Caitlin M Brumfiel; Meera H Patel; Bashar Aqel; Michael Lehrer; Samir H Patel; Mahesh Seetharam
Journal:  JAAD Case Rep       Date:  2021-06-04

5.  HNRNPCL1, PRAMEF1, CFAP74, and DFFB: Common Potential Biomarkers for Sporadic and Suspected Lynch Syndrome Endometrial Cancer.

Authors:  Yuan Gao; Xiuping Zhang; Tian Wang; Ye Zhang; Qingxuan Wang; Yuanjing Hu
Journal:  Cancer Manag Res       Date:  2020-11-04       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.